Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Everything that you are ever going to want to know about running shoes: Running Shoes Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
  2. Have you considered the Critical Thinking and Skeptical Boot Camp, for taking it to the next level? See here for more.
    Dismiss Notice
  3. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Smith & Nephew Will End Dermagraft Production

Discussion in 'Diabetic Foot & Wound Management' started by admin, Dec 8, 2005.

  1. admin

    admin Administrator Staff Member


    Members do not see these Ads. Sign Up.
    An email news alert from Advances in Skin and Wound Care is reporting:

    I can't find an announcement on the Smith & Nephew website and Dermagraft is still listed:
    http://wound.smith-nephew.com/au/Product.asp?NodeId=3472
    All I can find is this snippet from the October 25 Q3 financial report:
    http://www.smith-nephew.com/news/item.jsp?id=272
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Advanced BioHealing Announces Purchase of Dermagraft(R) and TransCyte(R)
    Wednesday May 31, 12:00 pm ET
     
  3. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release;
    Advanced BioHealing Launches Dermagraft(R)Thursday February 15, 10:00 am ET
     
  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Looks like its selling well:

    Press Release:
    Safeguard Scientifics Announces Third Quarter 2008 Financial Results
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Arkansas AG Reaches Settlement with Shire Pharmaceuticals
    The State of Arkansas is Due to Receive Over $269,000

    LITTLE ROCK, Ark. (News release) – Arkansas Attorney General Leslie Rutledge has reached a settlement with Shire Pharmaceuticals LLC and other subsidiaries of Shire PLC, resolving allegations that Shire and the company it acquired in 2011, Advanced BioHealing, employed kickbacks and other unlawful methods to promote Dermagraft. A bioengineered human skin substitute, Dermagraft is approved by the Food and Drug Administration for the treatment of diabetic foot ulcers.

    Shire will pay the federal government $350 million, of which $14.5 million will go to the Medicaid program to resolve allegations that Shire’s improper promotion of the drug caused false claims to be submitted to government health care programs. The states will receive $6,104,000, of which Arkansas will receive $269,018.80.

    “The alleged actions of Shire were not only unlawful but ethically wrong,” said Attorney General Rutledge. “Medications should be prescribed to patients because it is in the interest of their health – not because it leads to more lavish dinners, drinks, medical equipment, travel and many other items for the clinics and staff.”

    According to the federal government, this is the largest False Claims Act recovery by the U.S. in a kickback case involving a medical device. This settlement resolves allegations that Dermagraft salespersons unlawfully induced clinics and physicians with dinners, drinks, entertainment and travel, medical equipment and supplies, as well as unwanted payments for purported speaking engagements and bogus case studies, in addition to cash, credits and rebates to induce the use of the drug. The federal Anti-Kickback statute prohibits, among other things, the payment of remuneration to induce the use of medical devices covered by Medicare, Medicaid and other federally funded health care programs.

    In addition to kickback allegations, the settlement resolves allegations that Shire and its predecessor unlawfully marketed Dermagraft for uses not approved by the FDA, made false statements to inflate the price of the drug and caused improper coding, verification or certification of Dermagraft claims and related services.

    A National Association of Medicaid Fraud Control Units team participated in the investigation and conducted the negotiations on behalf of the states. The team included representatives of the Florida, Illinois, New York and Ohio Medicaid Fraud Control Units. The investigation was coordinated in conjunction with the U.S. Department of Justice Commercial Litigation Branch and the U.S. Attorneys’ Offices for the District of Columbia, Middle District of Florida and Eastern District of Pennsylvania.
     
Loading...

Share This Page